Compare Inovio Pharmaceuticals Inc (INO) vs Nucor Corporation (NUE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Nucor Corporation — how do they compare? Inovio Pharmaceuticals Inc trades at $1.15 (market cap $112.19M), while Nucor Corporation trades at $250.33 (market cap $55.84B). The key difference: Nucor Corporation is far larger — about 497.7× Inovio Pharmaceuticals Inc's market cap, and Nucor Corporation pays a 0.91% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and Nucor Corporation for 78 Days on average.
| INO | NUE | |
|---|---|---|
Market Cap | $112.19M | $55.84B |
Volume | 3,201,278 | 848,835 |
Sector | Health | Basic Materials |
52-Week High | $2.60 | $274.74 |
52-Week Low | $0.66 | $131.78 |
Typical Hold Time | 43 Days | 78 Days |
Enterprise Value | $83.51M | $60.25B |
Dividend Yield | — | 0.91% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.09, down 5.63% today, with a bearish technical outlook and negative financial metrics including a net income margin of -130,000% and ROE of -409.87%. The company faces significant fundamental challenges with minimal revenue of $65,340 and substantial losses, though recent earnings have beaten expectations. Key near-term catalyst is the FDA decision on INO-3107 by October 30, 2026.
Despite analyst consensus favoring Buy ratings (58.83%) with a $2.75 price target, INO carries high risk due to persistent cash burn, negative profitability, and dependency on regulatory approvals. The stock offers speculative upside if INO-3107 gains approval but remains vulnerable to further dilution and operational setbacks.
Nucor (NUE) trades at $246.14, down 0.12% on the day, with a bearish technical signal from moving averages despite recent earnings beats. The company reported strong Q2 2026 EPS of $4.84, beating expectations, and issued Q3 2026 guidance anticipating higher earnings. Revenue is projected to grow to $36.1B in 2026, with net income margin improving to 7.98%. Analyst consensus is a 'Moderate Buy' with a $266.88 price target, suggesting potential upside from current levels.
The outlook for NUE is cautiously optimistic, supported by earnings momentum and steel price strength, but tempered by competitive pressures and cyclical industry risks. Investment opportunity lies in execution of growth initiatives and dividend consistency, while key risks include economic sensitivity and new capacity additions in the steel sector impacting pricing power.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Nucor Corporation
Nucor Corp manufactures steel and steel products. The company also produces direct reduced iron for use in its steel mills. The operations include international trading and sales companies that buy and sell steel and steel products manufactured by the company and others. The operating business segments are: steel mills, steel products and raw materials, the steel mills segment derives maximum revenue.
Read more on NUE →
